Mu.Ta.Lig - COST ACTION CA15135

Prof. Maurizio BOTTA

14 June 2016


General information

Name: Maurizio
Surname: Botta
Cell phone number with international prefix: +39 328 0091722
Country: Italy
Affiliation: University of Siena
Gender: F □ M
Year of the PhD title: 1979
Personal web page: http://
Previous COST participation: No □ Yes


List of 10 selected publications within last 5 years

1.      Brai A, Fazi R, Tintori C, Zamperini C, Bugli F, Sanguinetti F, Stigliano E, Esté J, Badia R, Franco S, Martinez M A, Martinez J, Meyerhans A, Saladini F, Zazzi M, Garbelli A, Maga G, and Botta M, Human DDX3 Protein: a New Valuable Target to Develop Broad Spectrum Antiviral Agents. PNAS, in press.
2.      Trist IML, Nannetti G, Tintori C, Fallacara AL, Deodato D, Mercorelli B, Palù G, Wijtmans M, Gospodova T, Edink E, Verheij M, de Esch I, Viteva L, Loregian A, Botta M. 4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA–PB1 Protein–Protein Interaction: Structure–Activity Relationships Exploration with the Aid of Molecular Modeling. J. Med. Chem. 2016, 59(6): 2688-2703.


3.      Vignaroli, G., Calandro, P., Zamperini, C., Coniglio, F., Iovenitti, G., Tavanti, M., Colecchia, D., Dreassi, E., Valoti, M., Schenone, S., Chiariello, M., Botta, M. Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: Nanosystem approaches for drug delivery. Scientific Reports 2016, 6, art. no. 21509.
4.      Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma. Tintori, Cristina; Fallacara, Anna Lucia; Radi, Marco; Zamperini, Claudio; Dreassi, Elena; Crespan, Emmanuele; Maga, Giovanni; Schenone, Silvia; Musumeci, Francesca; Brullo, Chiara; Botta, M. From Journal of Medicinal Chemistry 2015, 58(1), 347-361
5.      Structure prediction and validation of the ERK8 kinase domain. Strambi, Angela; Mori, Mattia; Rossi, Matteo; Colecchia, David; Manetti, Fabrizio; Carlomagno, Francesca; Botta,Maurizio; Chiariello, Mario PLoS One (2013), 8(1), e52011
6.      M Mori, A Nucci, MCD Lang, N Humbert, C Boudier, F Debaene, S Sanglier-Cianferani, M Catala, P Schult-Dietrich, U Dietrich, C Tisné, Y Mely, M Botta Functional and Structural Characterization of 2-Amino-4-phenylthiazole Inhibitors of the HIV-1 Nucleocapsid Protein with Antiviral Activity ACS Chemical Biology, 2014, 19;9(9), 1950-5


7.      Biologically Driven Synthesis of Pyrazolo [3, 4-d] pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies. S Schenone, M Radi, F Musumeci, C Brullo, M Botta  Chemical reviews 2014, 114 (14), pp 7189–7238.


8.      Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus.  Kessler, Ulrich; Castagnolo, Daniele; Pagano, Mafalda; Deodato, Davide; Bernardini, Martina; Pilger, Beatrice; Ranadheera, Charlene; Botta, Maurizio. Bioorganic & Medicinal Chemistry Letters (2013), 23(20), 5575-5577
9.      Design, Synthesis, and Biological Evaluation of Pyrazolo[3,4-d]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant. Radi, Marco; Tintori, Cristina; Musumeci, Francesca; Brullo, Chiara; Zamperini, Claudio; Dreassi, Elena; Fallacara, Anna Lucia; Vignaroli, Giulia; Crespan, Emmanuele; Zanoli, Samantha;  Botta, M. Journal of Medicinal Chemistry (2013), 56(13), 5382-5394
10.   Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. Poce, Giovanna; Bates, Robert H.; Alfonso, Salvatore; Cocozza, Martina; Porretta, Giulio Cesare; Ballell, Lluis; Rullas, Joaquin; Ortega, Fatima; De Logu, Alessandro; Agus, Emanuela; Botta, M. et al. PLoS One (2013), 8(2), e56980


Main skills and expertise (up to 5)

1. Antivirals
2. Anticancer
3. Antibacterial& antifungal
4. Computational Studies, modeling
5. Analytical Chemistry


Main equipment/facilities available in the participants’ lab (up to 5)

1.      Synthesis laboratory equipped with main common equipment and with CEM Liberty Microwave Peptide Synthesizer, DISCOVER SP – MICROWAVE SYNTHESIZER.
2.      Computational laboratory equipped with 5 Workstations for modelling studies, software
3.      Analytical laboratory: HPLC- UV-MS, HPLC-MS-MS, GC-MS
4.      ADMET facilities
5.       Facilities for Preclinical studies















Short personal activity proposal for the COST Action CA15135 (max 1000 characters)

The team leaded by Prof. Botta at the University of Siena has been developing novel strategies for the design, synthesis and drug-likeness assessment of novel potential drugs for almost 30 years. Acknowledging the importance of interdisciplinary in the design of effective compounds, the group includes three divisions (molecular modelling, organic chemistry and analytical chemistry/drug delivery) that work in team for the development of the design of several different compounds with anticancer, anti-fungal, antibiotic, anti-asthma and antiviral activity. Profiting of the great experience in drug design, the group will design/optimize potential drugs able to selectively target more than one macromolecule involved in the pathogenesis of a disease, aiming a synergic effect. For this scope, of particular importance will be the use of the most advanced molecular modelling techniques that will guide the in-house synthesis of new molecules. Furthermore, the increasing experience in the development of advanced drug delivery systems will be exploited to direct active compounds to the desired targets, improving selectivity.




Work Group preference: score from 1 (preferred) to 4 (not preferred)

Work Group of the CA15135 COST Action Score
WG1: Development of new chemical entities 1
WG2: Selection of biological targets and assessment of biological data 2
WG3: Development of chemical databases 4
WG4: Development of Computational methods for multiple ligand design and discovery 3